Non-pulmonary vein foci induced before and after pulmonary vein isolation in patients undergoing ablation therapy for paroxysmal atrial fibrillation: incidence and clinical outcome

J Zhejiang Univ Sci B. 2014 Oct;15(10):915-22. doi: 10.1631/jzus.B1400146.

Abstract

Objective: To evaluate the incidence and clinical outcome of adenosine triphosphate (ATP) plus isoproterenol (ISP)-induced non-pulmonary vein (PV) foci before and after circumferential PV isolation (CPVI) during index ablation in patients with paroxysmal atrial fibrillation (PAF).

Methods: In 80 consecutive patients undergoing catheter ablation for drug-refractory, symptomatic PAF at our hospital from April 2010 to January 2011, atrial fibrillation (AF) was provoked with ATP (20 mg) and ISP (20 µg/min) administration before and after CPVI. The spontaneous initiation of AF was mapped and recorded.

Results: Before ablation, AF mostly originating from PVs (PV vs. non-PV, 36/70 vs. 3/70; P<0.01) was induced in 39 patients with sinus rhythm. CPVI significantly suppressed AF inducibility; however, more non-PV foci were provoked (post-CPVI vs. pre-CPVI, 13/76 vs. 3/70; P=0.016). Patients with pre- and post-CPVI induced AF (n=49) were divided according to non-PV foci being induced (group N, n=17) or not (group P, n=32). After mean (19.2±8.2) months follow-up, 88.2% (15/17) and 65.6% (21/32) of patients in groups N and P, respectively, were free from AF recurrence (P=0.088).

Conclusions: ATP+ISP administration effectively provokes non-PV foci, especially after CPVI in PAF patients. Although in this study difference did not achieve statistical significance, supplementary ablation targeting non-PV foci might benefit clinical outcome.

Keywords: Adenosine triphosphate; Atrial fibrillation; Non-pulmonary vein foci.

Publication types

  • Clinical Trial

MeSH terms

  • Adenosine Triphosphate
  • Atrial Fibrillation / diagnosis*
  • Atrial Fibrillation / prevention & control
  • Atrial Fibrillation / surgery*
  • Cardiotonic Agents
  • Catheter Ablation / methods*
  • Female
  • Heart Conduction System / surgery*
  • Humans
  • Incidence
  • Isoproterenol
  • Male
  • Pulmonary Veins / surgery*
  • Recurrence
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Treatment Failure
  • Treatment Outcome

Substances

  • Cardiotonic Agents
  • Adenosine Triphosphate
  • Isoproterenol